• BIVDA members area

Members' Press Releases

QuantuMDx receives grant funding from Gates Foundation for diagnostic to reach the missing 4.3 million TB cases a year

28th November 2016, Newcastle upon Tyne, UK. QuantuMDx announced today that it received funding from the Bill & Melinda Gates Foundation to further develop and test its CAPTURE-XT™ pathogen concentration technology and Q-POC™ molecular diagnostic (MDx) platform for rapid low cost TB detection and drug susceptibility testing (DST) in response to World Health Organisation target product profiles. The technology is being developed for introduction into peripheral microscopy centres, clinics and hospitals in high burden countries, finally providing a low cost MDx solution to reach the 4.3 million people with TB who are ‘missed’ by healthcare systems each year.

The project will bring together experts from QuantuMDx, the Gates Foundation’s TB Program, FIND, Yale University and St George’s University of London, to further develop and test the CAPTURE-XT™ and Q-POC™ technologies on a blinded cohort of FIND’s well-characterized sputum samples. The ultimate aim is to seamlessly integrate Q-POC™ technologies into existing microscopy centres for the rapid detection of TB and DST.  

 “Our CAPTURE-XT™ and Q-POC™ platforms will make gold standard TB detection and DST accessible throughout low to middle income countries (LMICs) offering a tangible hope of meeting international TB eradication targets” said Inventor and Chief Scientific Officer Jonathan O’Halloran. He continued, “Sample preparation and detection of TB at low bacterial concentrations and at low cost is notoriously difficult. Our technology achieves this and looks set to shake up the TB testing market for the first time in a decade, taking high-sensitivity testing to the point of care and at a price point accessible by all.”

QuantuMDx’s CEO Elaine Warburton OBE said “We are thrilled that the Gates Foundation is funding this project. A 2015 KPMG report estimated that, without urgent action, some 75 million additional people could die of TB over the next 35 years, at a global economic cost of $16.7 trillion. This is simply unacceptable, and the costs are unsustainable. I believe our Q-POC™ technologies will truly provide that elusive solution to early TB detection leading to quick and precise treatment thus reducing disease transmission and death.” www.quantumdx.com

Comments are closed for this post, but if you have spotted an error or have additional info that you think should be in this post, feel free to contact us.